Rechercher des projets européens

22 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)

Date du début: 1 oct. 2013, Date de fin: 31 mars 2020,

Traumatic Brain Injury (TBI) is a major cause of death and disability, leading to great personal suffering to victim and relatives, as well as huge direct and indirect costs to society. Strong ethical, medical, social and health economic reasons therefore exist for improving treatment. The CENTER-TBI project will collect a prospective, contemporary, highly granular, observational dataset of 5400 p ...
Voir le projet

 44

 TERMINÉ 

Labeling of Enalapril from Neonates up to Adolescents (LENA)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Children are often treated as small adults—not as the special patients they are. Regulations exist to encourage the development of drugs and formulation for children. However, off-patent drugs are often administered to children without appropriate formulations or systematic investigations. Therefore, the paediatric use marketing authorisation (PUMA) has been designed.The EMA Paediatric Working Par ...
Voir le projet

 14

 TERMINÉ 

Targets and biomarkers for antiepileptogenesis (EPITARGET)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a comb ...
Voir le projet

 20

 TERMINÉ 

Personalised Prognostic Tools for Early Psychosis Management (PRONIA)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,

Affective and non-affective psychoses have a major negative impact on human society. They account for 6.3% of the global burden of disease and cost €207 billion per year in Europe alone, making them the most expensive brain-related disorders and even more expensive than cardiovascular diseases. This socioeconomic burden is largely caused by two core disease features: onset in adolescence and early ...
Voir le projet

 13

 TERMINÉ 

MicroRNAs in the Pathogenesis, Treatment and Prevention of Epilepsy (EPIMIRNA)

Date du début: 1 sept. 2013, Date de fin: 31 août 2018,

Epilepsy is a major burden for patients and health systems worldwide. It is a common chronic neurological disorder affecting people of all ages, and the shortfall in existing treatments means that 30% of patients continue to suffer uncontrolled seizures. MicroRNAs (miRNA) are a recently-discovered, network-level layer of gene expression regulation that controls protein levels of entire signaling p ...
Voir le projet

 19

 TERMINÉ 

New approaches in the development of Hypoallergenic implant material in Orthopaedics: steps to personalised medicine (HYPORTH)

Date du début: 1 août 2013, Date de fin: 31 juil. 2018,

Europe is confronted by a demographic challenge as a decreasing work force has to support an increasing elderly population. The economic risk implied by this burden could be addressed by efforts to achieve an increase in Healthy Life Years. One key element would be to ensure unrestricted mobility for especially the elderly, allowing them to stay at work for longer. Irreversible joint deterioration ...
Voir le projet

 11

 TERMINÉ 

Neurobiology and Treatment of Adolescent Female Conduct Disorder: The Central Role of Emotion Processing (FEMNAT-CD)

Date du début: 1 sept. 2013, Date de fin: 28 févr. 2018,

Conduct Disorder (CD) and Oppositional Defiant Disorder with symptoms of Conduct Disorder (which is included among the abbreviation “CD” throughout the proposal) has a highly negative impact for the affected individual as well as for families and society. Although the number of females exhibiting serious aggressive behaviours is growing, the majority of studies on aetiology and treatment of CD hav ...
Voir le projet

 19

 TERMINÉ 

Bioactivated hierarchical hydrogels as zonal implants for articular cartilage regeneration (HYDROZONES)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

Degeneration of cartilage is a major cause of chronic pain, lost mobility and reduced quality of life for millions of European citizens. From a clinical point of view treatment to achieve cartilage regeneration (hyaline) and not only repair (fibrous) remains a great challenge. No clinical therapy is available that leads to healing of cartilage defects.Current cartilage implants cannot establish th ...
Voir le projet

 18

 TERMINÉ 

European Lead Factory (EUC²LID)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,

The European Lead Factory concept proposed by the EUC2LID Consortium relates to the discovery of novel small molecule candidates to serve as starting points for subsequent optimization to either drug candidates or high-quality pharmacological tools for the experimental validation of targets. The concept intends to bridge academic and applied research interests. The European Lead Factory will provi ...
Voir le projet

 34

 TERMINÉ 

Systems medicine of chronic inflammatory bowel disease (SYSMEDIBD)

Date du début: 1 déc. 2012, Date de fin: 30 nov. 2017,

Inflammatory bowel disease (IBD) is a major health problem with severe co-morbidities, requiring life-long treatment. Oscillating processes, like biological clocks are well studied and modeled in a number of systems. Circadian rhythms are extremely important for optimal treatments of patients. Recently, the NfkB pathway has been shown to be oscillating. In this project, we will model NfkB oscillat ...
Voir le projet

 13

 TERMINÉ 

Development and clinical trials of a new Software ENgine for the Assessment & Optimization of drug and non-drug Therapy in Older peRsons (SENATOR)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2017,

The European population of older people with multiple chronic diseases (multimorbidity) is increasing steadily in tandem with the rising population of people aged ≥ 65 years. Older multimorbid people are at high risk of polypharmacy (PP), inappropriate prescribing (IP), adverse drug reactions (ADRs) and adverse drug events (ADEs). PP, IP, ADRs and ADEs in turn cause excessive drug costs and excess ...
Voir le projet

 13

 TERMINÉ 

Management of Hypotension In the Preterm Extremely Low Gestational Age Newborn (THE HIP TRIAL)

Date du début: 1 oct. 2010, Date de fin: 30 sept. 2017,

Assuming an annual birth rate of 10.25 births/1,000 population approximately 25,000 Extremely Low Gestational Age Newborns are born every year in the EU. Conservative figures estimate that approximately half of all these babies will develop low blood pressure and require treatment. However, no uniform criteria exist to define hypotension and the evidence to support our current management strategie ...
Voir le projet

 17

 TERMINÉ 

Engine Module Validators (ENOVAL)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

The ENOVAL project will provide the next step of engine technologies to achieve and surpass the ACARE 2020 goals on the way towards Flightpath 2050. ENOVAL completes the European 7th Framework Programme (FP7) roadmap of Level 2 aero engine projects. ENOVAL will focus on the low pressure system of ultra-high by-pass ratio propulsion systems (12 < BPR < 20) in conjunction with ultra high overall pre ...
Voir le projet

 37

 TERMINÉ 

Multivessel versus culprit lesion only percutaneous revascularization in patients with acute myocardial infarction complicated by cardiogenic shock (CULPRIT-SHOCK)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) represents a major European health care concern with mortality rates between 40-70%. Approximately 70-80% of these patients present with multivessel disease defined as coronary lesions in more than one vessel. The clinician is faced with the decision to either 1) intervene only on the culprit lesion acutely responsible for the i ...
Voir le projet

 23

 TERMINÉ 

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS)

Date du début: 1 oct. 2013, Date de fin: 30 juin 2017,

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caus ...
Voir le projet

 15

 TERMINÉ 

Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Voir le projet

 17

 TERMINÉ 

European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS)

Date du début: 1 avr. 2012, Date de fin: 31 mars 2017,

Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core symptoms of autism spectrum disorder (ASD). Major obstructions to this include a lack of aetiologically-driven or pathophysiologically-accurate animal models; an absence of tests that indicate efficacy; and reliance of clinical trials on DSM/ICD10 categories wh ...
Voir le projet

 29

 TERMINÉ 

Donor T Cells for Immune Control (T-CONTROL)

Date du début: 1 mai 2013, Date de fin: 31 janv. 2017,

Patients with high-risk hematological tumors can be cured by allogeneic hematopoietic stem cell transplantation (HSCT). However, the main causes of failure of HSCT are infections, tumor relapse and over-shooting immune responses of the donor T cells to healthy cells and tissues of the patient or graft-versus host disease (GvHD). Therefore, this treatment is still associated with a high morbidity a ...
Voir le projet

 6

 TERMINÉ 

EUROPEAN FORENSIC GENETICS Network of Excellence (EUROFORGEN-NOE)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

The EUROFORGEN-NoE proposal aims to develop a network of excellence for the creation of a European Virtual Centre of Forensic Genetic Research. Forensic genetics is a highly innovative field of applied science with a strong impact on the security of citizens. However, the genetic methods to identify offenders as well as the creation of national DNA databases have caused concerns to the possible vi ...
Voir le projet

 19

 TERMINÉ 

A novel generation of skin substitutes to clinically treat a broad spectrum of severe skin defects (EUROSKINGRAFT)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,

Large full-thickness skin defects resulting from burns, soft tissue trauma, congenital giant nevi, tumour resection, and disease leading to skin necrosis, represent a significant and common clinical problem worldwide. This problem is far from being solved. The main challenge encountered is that most autologous skin grafting techniques are based on transplanting split-thickness skin (the today’s go ...
Voir le projet

 11

 TERMINÉ 

European Network for the Study of Adrenal Tumours - Structuring clinical research on adrenal cancers in adults (ENS@T-CANCER)

Date du début: 1 janv. 2011, Date de fin: 30 juin 2016,

Among patients with adrenal masses Adrenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH) are found with a low incidence but very unfavorable prognosis. Due to this poor clinical outcome, concomitant hormone dysregulation and limited treatment options the two cancer entities severely impact on affected patients. However, the rarity of the tumors also impedes clinical studies which ar ...
Voir le projet

 17

 TERMINÉ 

Solar chemical reactor demonstration and Optimization for Long-term Availability of Renewable JET fuel (SOLAR-JET)

Date du début: 1 juin 2011, Date de fin: 31 oct. 2015,

The aim of the SOLAR-JET project is to demonstrate a carbon-neutral path for producing aviation fuel, compatible with current infrastructure, in an economically viable way. The SOLAR-JET project will demonstrate on a laboratory-scale a process that combines concentrated sunlight with CO2 captured from air and H2O to produce kerosene by coupling a two-step solar thermochemical cycle based on non-st ...
Voir le projet

 6